The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Immunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466 · cited 7×
“Tugues S, Burkhard SH, Ohs I et al. New insights into IL-12-mediated tumor suppression.”
BackgroundInfluentialIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · cited 1×
“The immune system plays a prognostic role in ovarian cancer (1-3) and accumulating evidence suggests that immunotherapy in combination with chemotherapy holds potential for improved clinical outcomes in EOC (4, 5).”
BackgroundImmunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Dijkgraaf, E. M., Heusinkveld, M., Tummers, B., Vogelpoel, L. T. C., Goedemans, R., Jha, V., Nortier, J. W. R., Welters, M. J. P., Kroep, J. R., & van der Burg, S. H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3542 · Cited by 346 · cited 3×
“Whereas the immunological changes and clinical outcome observed fit into the model of better tumor control through revamping of immunity, tocilizumab may also have acted directly on tumor growth by blocking IL-6 signaling in the tumor cells as we have previously demonstrated [9].”
BackgroundSelf-citation
Cited by
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290
Interleukins in cancer: from biology to therapy
Briukhovetska, D., Dörr, J., Endres, S., Libby, P., Dinarello, C. A., & Kobold, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00363-z · Cited by 781
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709
Self-citationMace, T. A., Shakya, R., Pitarresi, J. R., Swanson, B., McQuinn, C. W., Loftus, S., Nordquist, E., Cruz-Monserrate, Z., Yu, L., Young, G., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-311585 · Cited by 539
Targeting the microenvironment in solid tumors
Belli, C., Trapani, D., Viale, G., D'Amico, P., Duso, B. A., Della Vigna, P., Orsi, F., & Curigliano, G. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.02.004 · Cited by 496
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors
Kaur, S., Bansal, Y., Kumar, R., & Bansal, G. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115327 · Cited by 449
Aliyu, M., Zohora, F. T., Anka, A. U., Ali, K., Maleknia, S., Saffarioun, M., & Azizi, G. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109130 · Cited by 401
Patente, T. A., Pinho, M. P., Oliveira, A. A., Evangelista, G. C. M., Bergami-Santos, P. C., & Barbuto, J. A. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03176 · Cited by 392
IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy
Weber, R., Groth, C., Lasser, S., Arkhypov, I., Petrova, V., Altevogt, P., Utikal, J., & Umansky, V. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104254 · Cited by 309
Kitamura, H., Ohno, Y., Toyoshima, Y., Ohtake, J., Homma, S., Kawamura, H., Takahashi, N., & Taketomi, A. (2017) · Cancer Science · doi:10.1111/cas.13332 · Cited by 278
Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery
Hu, Y., Dong, Z., & Liu, K. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02949-5 · Cited by 268
IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma
Xu, J., Lin, H., Wu, G., Zhu, M., & Li, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.760971 · Cited by 228
Tumor microenvironment in ovarian cancer: function and therapeutic strategy
Yang, Y., Yang, Y., Yang, J., Zhao, X., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00758 · Cited by 218
Mesenchymal stroma: Role in osteosarcoma progression
Cortini, M., Avnet, S., & Baldini, N. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.07.024 · Cited by 171
Natural products as IL‐6 inhibitors for inflammatory diseases: Synthetic and SAR perspective
Harmalkar, D. S., Sivaraman, A., Nada, H., Lee, J., Kang, H., Choi, Y., & Lee, K. (2024) · Medicinal Research Reviews · doi:10.1002/med.22022 · Cited by 23
Metadata
- Authors
- Dijkgraaf, E. M., Santegoets, S. J. A. M., Reyners, A. K. L., Goedemans, R., Wouters, M. C. A., Kenter, G. G., van Erkel, A. R., van Poelgeest, M. I. E., Nijman, H. W., van der Hoeven, J. J. M., Welters, M. J. P., van der Burg, S. H., & Kroep, J. R.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2015-10
- Volume
- 26
- Issue
- 10
- Pages
- 2141-2149
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W1857903828
- Cited by
- 197
- References
- 5
- FWCI
- 14.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.